APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Recruiting · NCT04785196 · Registry updated 2025-02-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, liposarcoma, neoplasm, sarcoma | Recruiting | Phase 1 / Phase 2 | 2025-02-26 | NCT04785196 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ascentage Pharma Group Inc. | 30 |
| Suzhou Yasheng Pharmaceutical Co., Ltd. | 8 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital of The University of Chinese Academy of Sciences | Hangzhou | China | 2 |
| Shanghai East Hospital (East Hospital affiliated to Tongji University) | Shanghai | China | 1 |
| Sun Yat-Sen University Cancer Center | Guangzhou | China | 113 |